GlassScriptPhysician profile
Sunil K Kaushal
NPI 1376597369
$9,586.25
in general payments reported to CMS, 2019-2025
28 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $910 · 2021: $1,196 · 2022: $1,158 · 2023: $1,687 · 2024: $2,094 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,632 · Education: $438 · Gift: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,632.36 |
| Education | $438.29 |
| Gift | $327.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,626.37 | 2019-2025 | |
| Gilead Sciences, INC. | $1,154.53 | 2019-2025 | Livdelzi, Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $928.69 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Braintree Laboratories, INC. | $867.99 | 2019-2024 | Sutab, Suflave |
| Janssen Biotech, INC. | $539.42 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.41 | 2019-2024 | Xifaxan |
| Pfizer INC. | $310.98 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $276.72 | 2019-2024 | Ocaliva |
| Celgene Corporation | $218.69 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $203.77 | 2020-2024 | Linzess |
| Genzyme Corporation | $193.25 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.01 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $83.61 | 2020-2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $74.61 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $64.55 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $63.96 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $56.95 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $55.40 | 2020 | |
| Evoke Pharma, INC. | $49.53 | 2022-2023 | Gimoti |
| Amgen INC. | $48.78 | 2022-2023 | Amjevita, Avsola |
| Alexion Pharmaceuticals, INC. | $38.41 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $37.86 | 2020-2021 | |
| Madrigal Pharmaceuticals | $34.39 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $30.39 | 2024 | Voquezna |
| Shionogi INC | $29.93 | 2019 | |
| Allergan, INC. | $26.73 | 2019 | |
| Lilly USA, LLC | $24.37 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $17.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Kaushal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.